Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.46 |
| ▸ | F7 | P08709 | 7/20 | 0.45 |
| ▸ | F3 | P13726 | 7/20 | 0.45 |
| ▸ | F2 | P00734 | 5/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590750 | 0.85 | KDM4E (0.48) | KDM4EHSD17B10AKR1B10F7F3 | |
| SCHEMBL23460607 | 0.84 | F7 (0.63) | F7F3F2 | |
| SCHEMBL14648291 | 0.83 | F7 (0.63) | KDM4EHSD17B10F7F3F2 | |
| SCHEMBL23511239 | 0.82 | F7 (0.67) | F7F3F2 | |
| SCHEMBL5847598 | 0.81 | F2 (0.50) | F7F3F2 | |
| SCHEMBL2145480 | 0.81 | F7 (0.65) | F7F3F2 | |
| SCHEMBL5848054 | 0.79 | F7 (0.67) | F7F3F2 | |
| SCHEMBL5847557 | 0.77 | F7 (0.52) | F7F3F2 | |
| SCHEMBL7398979 | 0.72 | ALDH1A1 (0.41) | KDM4EAKR1B10 | |
| SCHEMBL5847414 | 0.72 | F7 (0.51) | F7F3F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056498-A1 | SUBSTITUTED MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-03-04 | — | — | US | disclosed |
| US-7629338-B2 | Substituted monocyclic CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7625901-B2 | Substituted monocyclic CGRP receptor antagonists | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080318927-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2008-12-25 | — | — | US | disclosed |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056498-A1 | SUBSTITUTED MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | QRFPR, CALCRL, EDNRB | KDM4E 1758/4885HSD17B10 4383/4885AKR1B10 1331/4885 |
| US-20080318927-A1 | Substituted monocyclic CGRP receptor antagonists | EDNRB, CALCRL, QRFPR | KDM4E 1761/4885HSD17B10 4384/4885AKR1B10 1259/4885 |
| US-20070265225-A1 | Substituted monocyclic CGRP receptor antagonists | QRFPR, CALCRL, EDNRB | KDM4E 1758/4885HSD17B10 4383/4885AKR1B10 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.